The Trump administration is expected to move to reclassify cannabis as soon as Wednesday, making it easier to research medicinal applications of the plant, Axios’ Josephine Walker and Marc Caputo report, citing an administration official familiar with the matter. The news comes after Trump issued an executive order last year to reclassify cannabis as a Schedule III drug. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IGC Pharma (IGC), Tilray (TLRY), Trees Corporation (CANN) and Trulieve Cannabis (TCNNF).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Aurora Cannabis Buys EU GMP Producer Safari Flower Company in $26.5 Million Deal
- Canada’s Aurora Cannabis (ACB) Looks Overseas As Domestic Market Goes Up in Smoke
- Aurora Cannabis Buys Safari Flower to Boost EU GMP Supply for Global Medical Markets
- Aurora Cannabis Earns Repeat Honour for Executive Gender Diversity
- Congressman introduces bill for cannabis businesses to list on stock exchanges